This Phase II trial is trying to understand the effect of chemotherapy (obinutuzumab and atezolizumab) with or without radiotherapy in people with advanced follicular lymphoma.
This trial is treating patients with follicular lymphoma.
This is a radiotherapy and systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
Other Non-Commercial Sponsor
Olivia Newton-John Cancer Research Institute
This is a non-randomised trial with one experimental arm. All participants will receive an intravenous infusion of Obinutuzumab (1000mg) + Atezolizumab (1200mg) q3/52 x 6 cycles (plus 1000mg Obinutuzumab on day 8 and 15 of cycle 1). Responding participants (those with a partial response (PR) or stable disease (SD)) who do not achieve a CR at the end of cycle 2 will receive involved site radiotherapy (4Gy, 2 fractions) between cycle 3 and 4. At the end of cycle 6 and completion of the induction phase, responding participants (CR/PR/SD) will receive maintenance phase Obinutuzumab (1000mg intravenously) q8/52 for up to 12 cycles.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More